Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study |
Inal, Ali
(Department of Medical Oncology, Dicle University)
Kaplan, M. Ali (Department of Medical Oncology, Dicle University) Kucukoner, Mehmet (Department of Medical Oncology, Dicle University) Urakci, Zuhat (Department of Medical Oncology, Dicle University) Guven, Mehmet (Department of Internal Medicine, Dicle University) Nas, Necip (Department of Internal Medicine, Dicle University) Yunce, Muharrem (Department of Biochemistry, Dicle University) Isikdogan, Abdurrahman (Department of Medical Oncology, Dicle University) |
1 | Andreyev HJ, Norman AR, Oates J, Cunningham D (1998). Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer, 34, 503-9. DOI |
2 | Chau I, Norman AR, Cunningham D, et al (2004). Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol, 15, 2395-403. |
3 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90 DOI |
4 | Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8. DOI ScienceOn |
5 | Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH (2005). Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol, 23, 175-83. DOI |
6 | Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. JCO, 24, 2137-50. DOI ScienceOn |
7 | Kanagavel D, Pokataev IA, Fedyanin MY, et al (2010). A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol, 21, 1779-85. DOI |
8 | Kim JG, Ryoo BY, Park YH, et al (2008). Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol, 61, 301-7 |
9 | Krishnan S, Rana V, Janjan NA, et al (2006). Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 107, 2589-96. DOI ScienceOn |
10 | Lee J, Lim T, Uhm JE, et al (2007). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol, 18, 886-91. DOI |
11 | Maroufizadeh S, Maroufizadeh S, Hajizadeh E, Baghestani AR, Fatemi SR (2011). Multivariate analysis of prognostic factors in gastric cancer patients using additive hazards regression models. Asian Pac J Cancer Prev, 12, 1697-702. |
12 | Mitry E, Douillard JY, van Cutsem E, et al (2004). Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol, 15, 1013-7. DOI |
13 | Murad AM, Santiago FF, Petroianu A, et al (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 72, 37-41. DOI ScienceOn |
14 | Roth AD, Fazio N, Stupp R, et al (2006). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol, 25, 3217-23. |
15 | Park SH, Lee J, Lee SH, et al (2006). Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based firstline chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol, 57, 91-6. DOI |
16 | Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995). Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71, 587-91. DOI |
17 | Roshanaei G, Ghannad MS, Jafarabadi MA, Faradmal J, Sadighi S (2011). Prognostic impact of risk factors in patients with gastric cancer in Iran. Asian Pac J Cancer Prev, 12, 3005-8. |
18 | Roshanaei G, Ghannad MS, Jafarabadi MA, Faradmal J, Sadighi S (2011). Prognostic impact of risk factors in patients with gastric cancer in Iran. Asian Pac J Cancer Prev, 12, 3005-8. |
19 | Sadeghi B, Arvieux C, Glehen O, et al (2000). Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer, 88, 358-63. DOI |
20 | Sougioultzis S, Syrios J, Xynos ID, et al (2010). A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol, 21, 1779-85. DOI |
21 | Tsujitani S, Oka S, Suzuki K, et al (2001). Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: a multivariate analysis. Hepatogastroenterology, 48, 1504-8. |
22 | Yoshida M, Ohtsu A, Boku N, et al (2004). Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol, 34, 654-9. DOI |
23 | Van Cutsem E, Moiseyenko VM, Tjulandin SA, et al (2006). V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol, 24, 4991-7. DOI ScienceOn |
24 | Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9 DOI |